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Abstract
Background: Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer
(LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used
serum marker in breast cancer.
Methods: We retrospectively investigated the role of CA 15-3 in conjunction with other clinico-
pathological variables as a predictor of response and time to disease recurrence following
treatment in LABC. Pre and post primary chemotherapy serum concentrations of CA 15-3
together with other variables were reviewed and related to four outcomes following primary
chemotherapy (clinical response, pathological response, time to recurrence and time to
progression). Persistently elevated CA 15-3 after PC was considered as consecutively high levels
above the cut off point during and after PC.
Results: 73 patients were included in this study. Patients received PC (AC or AC-T regimen) for
locally advanced breast cancer. 54 patients underwent surgery. The median follow up was 790 days.
Patients with high concentrations of CA 15-3 before PC treatment had a poor clinical (p = 0.013)
and pathological (p = 0.044) response. Together with Her-2/neu expression (p = 0.009) and tumour
lympho-vascular space invasion (LVI) (p = 0.001), a persistently elevated CA 15-3 post PC (p =
0.007) was an independent predictive factor of recurrence following treatment in LABC.
Conclusion: Elevated CA 15-3 level is predictive of a poor response to chemotherapy. In addition,
persistently elevated CA 15-3 levels post chemotherapy in conjunction with lympho-vascular
invasion and HER2 status predict a reduced disease free survival following treatment in locally
advanced breast cancer.
Background
A significant number of women present with locally
advanced breast cancer (LABC) despite efforts to promote
public awareness. The use of Primary chemotherapy (PC)
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was initially introduced in patients with LABC, and was
first reported in 1978 as part of a multidisciplinary
approach [1]. Many studies have subsequently demon-
strated the benefits of PC in this setting [2,3]. Much inter-
est has focused on the role of molecular and biological
markers in predicting response to PC [4-7], however the
precise role of these markers remains controversial. CA
15-3 is a serum-based product of the MUC1 gene and is
the most widely used serum marker for breast cancer [8].
Its preoperative levels predict adverse outcome in node
negative and node positive breast cancer [9]. Kurebayashi
et al have demonstrated that CA 15-3 may have a role in
monitoring response to chemotherapy in LABC [10]. This
was reinforced by Duffy et al, who suggested that the most
important role for CA 15-3 is in monitoring therapy in
patients with advanced breast cancer [9,11]. However the
precise role of CA15.3 in predicting response to PC and
time to disease recurrence in patients with LABC follow-
ing both PC and surgery is ill defined. Here we provide
evidence to support a role for CA15.3 in both conditions.
Methods
73 patients who presented with LABC between January
1999 and May 2005 were included. All patients received
primary chemotherapy in the oncology day clinic at St.
Vincent's University Hospital, Dublin, Ireland. All
patients were free from metastatic disease at the time of
diagnosis as determined by bone scanning, liver ultra-
sonography and chest x-ray. The histological diagnosis
was established either by core biopsy or excisional biopsy.
Data was obtained by reviewing the medical records of
these patients. The hospital local ethics committee
approval was obtained for the study.
Primary chemotherapy
Earlier patients 48 (65.7%) were treated with 6 cycles of
AC (Doxorubicin 60 mg/m2 and Cyclophosphamide 600
mg/m2 at day one and repeated every 21 days). Later
patients 25 (34.2%) were treated with 4 cycles of AC fol-
lowed by 4 cycles of Docetaxol 75 mg/m2 every 21 days).
Clinical response (CR)
Patients' response to PC was assessed by regular clinical
examinations during which the clinical progress was doc-
umented at each visit. The UICC criteria were used to
assess the clinical response [5]. Patients were divided into
complete or partial responders or as having static or pro-
gressive disease.
Surgery
Prior to surgery all patients were regularly assessed for
response both clinically and radiologically. All suitable
patients underwent surgery within 6–8 weeks after com-
pletion of PC. Fifty two patients underwent a modified
radical mastectomy and two patients underwent breast
conserving surgery. Postoperatively all patients received
adjuvant chemotherapy (CMF regimen) and post opera-
tive radiotherapy.
Clinicopathological parameters
Variables analysed include tumour size, histological sub-
types, tumour grade, tumour stage, ER and Her-2/neu sta-
tus. ER status was determined by immunohistochemistry
using rabbit antihuman ERα antibody. Her2/neu status
was evaluated using the Dako Hercep Test immunocyto-
chemical assay. In tumor samples scoring +2 with the Her-
cep test, Her-2 status was confirmed by fluorescent in-situ
hybridization (FISH) test.
Pathological response (PR)
Chevallier's classification was used to evaluate pathologi-
cal response to PC [12]. Tumour size, lymph node
involvement, evidence of lymphovascular space invasion
(LVI), DCIS and tumour response to PC were docu-
mented.
CA15-3 levels
Serum CA 15-3 was measured by ELISA (ES300/Elecsys
2010; Roche Diagnostics). Variation was <6% for com-
mercial control sera (Preci Controls; Roche Diagnostics).
CA 15-3 concentrations were stratified using a cut off
value of 30 kilo units/L [9,13]. Serum CA 15-3 levels were
estimated at the time of diagnosis, following each cycle of
PC and every three months following surgery. A persist-
ently elevated CA 15-3 after chemotherapy is defined as
consecutive high levels of CA15-3 serum samples (steadily
rising or fluctuating levels) above the cut off point at the
time of completion of PC during the mentioned follow up
period prior to surgery.
Statistical analysis
SAS version 8.2 statistical program (SAS Institute, Cary,
North Carolina, USA) was used in the statistical analysis.
The clinical response was re-evaluated as follow: the com-
plete and partial clinical response was considered as a
good response while the static and progressive response
was considered as a poor response [5]. The pathological
response grading was also re-evaluated: Grade I and II
were considered as a good PR and grades III and IV as a
poor PR [14]. Univariate analysis was performed using
Fisher's exact test for categorical variables and Wilcoxon's
test for continuous variables. Multivariate analysis was
carried out using Cox's proportional hazard model. A P-
value of less than 0.05 was considered to be significant.
Results
Seventy three patients received primary chemotherapy for
LABC. The mean age was 52.3 years with a range from 26
to 96 years. The mean tumour size was 4.9 cm with a
range from 2–10 cm. The median follow up was 790 days.
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Table 1 illustrates the pathological parameters of tumours
in the studied group. The chemotherapeutic regimens
used did not influence the outcome.
Tumour markers
Twenty four patients had high serum levels of CA15-3
prior to chemotherapy. After completion of PC the serum
concentrations of CA 15-3 normalised in four patients,
one of these patients had bilateral inflammatory breast
cancer and did not undergo further surgery. The other
three patients underwent surgery and demonstrated a
favourable pathological response. All four patients were
alive at the end of the study with no disease recurrence.
Pre and post chemotherapy CA 15-3 levels did not corre-
late with any of the clinico-pathological parameters stud-
ied (Table 2).
Clinical response
The seventy three patients were categorised into four
groups according the UICC criteria based on response to
PC recorded on regular clinical examinations. A complete
clinical response was seen in 6 (8.2%) patients, partial
clinical response in 38 (52%) patients with no change
(stasis) from the original size in 24 (32.8%) patients and
progression in 5 (6.8%) patients. Multivariate analysis did
not show significance, however univariate analysis
showed that tumour stage (p = 0.014) and high levels of
serum CA15-3 before PC (p = 0.013) were significantly
associated with a poor clinical response to PC. Table (3)
demonstrates the relationship of poor clinical response to
the studied clinico-pathological variables.
Pathological response
Fifty four patients underwent surgery. At the end point of
the study, 19 patients were either awaiting surgery or were
deemed unsuitable for surgery. Using Chevallier's classifi-
cation there was a complete pathological response grade I,
in 4 (7.5%) patients. Five patients (9.4%) had a grade II
response, 21 (39.6%) patients had a grade III response
and 24 (45.2%) patients had a grade IV response. Groups
I and II were compared with groups III and IV. Multivari-
ate analysis failed to show significant relation between
pathological response and other variables. Tumour size,
the presence of lympho-vascular space invasion and high
levels of serum CA 15-3 before PC (p = 0.001, p = 0.034
and p = 0.044 respectively) were significantly associated
with an adverse pathological response to PC by univariate
analysis. Table (3) demonstrates the relationship of poor
pathological response to the clinico-pathological varia-
bles studied.
Table 1: Pathological parameters of the tumours in the 
investigated group.
Number %
Inflammatory carcinoma 24 32.8
Tumour type
Ductal 61 83.5
Lobular 8 10.9
Mixed 4 5.4
Tumour grade
I 1 1.37
II 27 36.9
III 45 61.6
LVI 26 35.6
Stage of the tumour
2 11 15
3 60 82.1
4 2 (SCL) 2.7
SCL (supraclavicular lymph nodes)
Table 2: The relation of high CA 15-3 concentration with the clinico-pathological variables analyzed.
High CA 15-3 before PC p value High CA 15-3 after PC p value
Tumour size
<2.5 cm 2/24(8.3%) 2/22(9.1%)
>2.5 cm 22/24(91.6%) 0.627 20/22(90.9%) 0.884
Tumour histology
Ductal 19/24(79.1%) 0.533 18/22(81.8%) 0.875
Lobular 4/24(16.6%) 3/22(13.6%)
Mixed 1/24(4.1%) 1/22(4.5%)
Tumour stage
II 2/24(8.3%) 1/22(4.5%)
III 20/24(83.3%) 0.266 20/22(90.9%) 0.256
IV 2/24(8.3%) 1/22(4.5%)
Her2/neu positive 5/24 (20.8%) 0.487 5/22(22.7%) 1.000
ER positive 14/24(58.3%) 1.000 12/22(54.5%) 0.796
LVI 10/24(41.6%) 0.603 11/22(50%) 0.114
Fisher's exact test was used for categorical variables and Wilcoxon's test for continuous variables. A P-value of less than 0.05 was considered to be 
significant. LVI (lympho-vascular space invasion) and PC (primary chemotherapy).
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Time to recurrence
Fifteen patients (20.5%) developed disease recurrence
after surgery during the study period; 5 patients developed
loco-regional recurrence and 10 patients developed dis-
tant organ metastasis. Ten of those who developed recur-
rence died from breast cancer. The median time to
recurrence was 630 days. Six patients of those with disease
recurrence had high levels of CA 15-3 before PC while
high post PC levels were found in nine patients. Using a
multivariate Cox proportional hazard analysis we found
that the presence of tumour LVI, Her-2/neu expression
and the presence of high serum levels of CA15-3 after PC
(p = 0.001, p = 0.009 and p = 0.007 respectively) were
three independent risk factors that significantly predict
time to disease recurrence after treatment in LABC, figures
1, 2 and 3 respectively.
Time to progression (TTP)
TTP was defined as the time from the initiation of treat-
ment till the disease progressed or death. Eighteen
patients had their disease progressed (15 patients had dis-
ease recurrence after surgery and three patients developed
disease progression after PC). Using Wilcoxon test high
levels of CA 15-3 before PC showed a borderline associa-
tion with TTP (P = 0.0575). However there was a signifi-
cant relation between high levels of CA 15-3 after PC and
TTP (p = 0.0001). No association was found between the
pathological response and TTP (P = 0.3408). However a
strong relation was found between the clinical response
and TTP (p = 0.0001).
Discussion
CA 15-3 is a serum based product for the MUC1 gene.
While CA 15-3 levels have previously been demonstrated
to predict outcome in LABC [15]. Its precise role defined
by clinical response, pathological response and disease
recurrence following PC treatment requires definition. In
a recent review Duffy et al concluded that the most impor-
tant application of CA 15-3 is in monitoring therapy in
patients with advanced breast cancer [11]. Expert panels
such as NACB and EGTM recommend the routine use of
CA 15-3 in monitoring therapy in patients with LABC
[16,17]. In contrast the routine use of CA 15-3 in LABC is
not recommended by the ASCO panel [18]. Here we pro-
vide evidence to support a role for CA 15-3 in LABC.
Much interest has focused on predictors of response to
treatment in LABC. Chang et al and Mauriac et al [19,20]
showed a favourable outcome in ER negative patients fol-
lowing treatment for LABC. We found no relation
between ER and clinical response however a borderline
relation was found between ER positive patients and poor
pathological response p = 0.052 (table 3), a larger sample
of patients may be needed to show a significant relation.
However these markers all require tumour tissue. CA 15-3
has the advantage of being a serum based marker and
therefore its measurement is less invasive. Kurebayashi et
al demonstrated that in pre-treatment CA15-3 positive
patients changes in CA 15-3 levels after systemic therapy
correlated with response to treatment [10]. Here we show
that a high CA 15-3 level before PC along with advanced
Table 3: The relation of poor clinical and pathological response to the clinico-pathological variables.
Poor clinical Response p value Poor pathological 
Response
p value
Tumour size
<2.5 cm 1/29(3.4%) 5/45(11%)
>2.5 cm 28/29(96.5%) 0.052 40/45(88.8%) 0.001
Tumour Histology
Ductal 26/29(89.6%) 0.216 40/45(74%) 0.187
Lobular 1/29(3.4%) 2/45(3.7%)
Mixed 2/29(6.8%) 3/45(5.5%)
Tumour stage
II 2/29(6.8%) 8/45(17.7%) 0.26
III 24/29(82.7%) 0.014 37/45(82.2%) 0.26
IV 3/29(10.3%) Non
Her2/neu positive 8/29(27.5%) 0.410 8/45(17.7%) 0.666
ER positive 18/29(62.1%) 0.396 32/45(91.4) 0.052
LVI 13/29(44.8%) 0.141 23/45(51.1%) 0.034
CA 15-3 before PC 13/29(50%) 0.013 17/45(37.7%) 0.044
CA 15-3 after PC 14/29(46.2%) 0.012 16/45(35.5%) 0.045
Fisher's exact test was used for categorical variables and Wilcoxon's test for continuous variables. A P-value of less than 0.05 was considered to be 
significant. LVI (lympho-vascular space invasion) and PC (primary chemotherapy).
BMC Cancer 2006, 6:220 http://www.biomedcentral.com/1471-2407/6/220
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tumour stage predict a poor clinical response to chemo-
therapy. A poor pathological response to chemotherapy is
predicted by elevated pre chemotherapy CA 15-3 levels,
large tumour size and the presence of lympho-vascular
invasion. Kurebayashi et al also demonstrated that a
greater than 20% reduction in CA 15-3 levels following
treatment was a favourable predictive factor for time to
disease progression during systemic therapy. In this study
we found that post chemotherapy high CA 15-3 levels
were associated with reduced time to disease progression.
We used a Cox proportional hazards model to identify
predictors of recurrence following both chemotherapy
and surgery in LABC. Detection of conventional markers
such as tumour size, lympho-vascular invasion and hor-
mone receptor status in addition to more recent parame-
ters such as HER2, KI-67 and p53 have all been associated
with outcome in LABC [19,20,4]. We found that lympho-
vascular invasion, HER2 status and elevated CA15-3 levels
post chemotherapy were independent predictors of a poor
outcome. De La Lande et al reported a relation between
CA 15-3 lead time and prognosis [21]. In this study we
report a predictive value of high CA 15-3 levels in LABC
following PC in relation to TTP and recurrence after sur-
gery. These findings may have important implications as
they suggest that surgery may be of minimal benefit in
patients who have persistently elevated CA15-3 levels fol-
lowing chemotherapy in LABC. It is not surprising that
HER2 status is an independent predictor of poor outcome
and this subgroup of patients would undoubtedly benefit
from Herceptin.
Conclusion
Elevated CA 15-3 levels predict a poor response to primary
chemotherapy in locally advanced breast cancer. In addi-
tion persistent elevation of CA 15-3, post chemotherapy,
in conjunction with the presence of lympho-vascular
invasion and HER2 positivity predict a reduced disease
free survival following treatment in locally advanced
breast cancer.
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Kaplan-Meiers survival curve, the expression of Her-2/neu 
receptor was associated with a decrease in disease free time 
(p = 0.009 Cox model).
Kaplan-Meiers survival curve shows that presence of LVI is significantly associated with shorter ime to r currence (p = 0.001 Cox model)Figure 1
Kaplan-Meiers survival curve shows that presence of LVI is 
significantly associated with shorter time to recurrence (p = 
0.001 Cox model).
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